These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 19537373)

  • 1. Treatment of facial lipoatrophy via autologous fat transfer.
    Cohen G; Treherne A
    J Drugs Dermatol; 2009 May; 8(5):486-9. PubMed ID: 19537373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correction of facial lipoatrophy using autologous fat transplants in HIV-infected adolescents.
    Dollfus C; Blanche S; Trocme N; Funck-Brentano I; Bonnet F; Levan P
    HIV Med; 2009 May; 10(5):263-8. PubMed ID: 19178590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Porcine filler for facial lipoatrophy associated with human immunodeficiency virus treatment.
    Reytan N; Rzany B
    J Drugs Dermatol; 2008 Sep; 7(9):884-6. PubMed ID: 19112805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A ribose-crosslinked collagen filler treatment for facial lipoatrophy associated with the treatment of human immunodeficiency virus.
    Reytan N; Rzany B
    J Drugs Dermatol; 2008 Dec; 7(12):1169-71. PubMed ID: 19137772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Facial lipohypertrophy in HIV-infected subjects who underwent autologous fat tissue transplantation.
    Guaraldi G; De Fazio D; Orlando G; Murri R; Wu A; Guaraldi P; Esposito R
    Clin Infect Dis; 2005 Jan; 40(2):e13-5. PubMed ID: 15655734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of facial lipoatrophy in HIV-infected patients.
    Prescrire Int; 2008 Aug; 17(96):170. PubMed ID: 19492497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Approaches to treatment of HIV facial lipoatrophy.
    Jones D
    Skin Therapy Lett; 2005 Nov; 10(9):5-7. PubMed ID: 16292459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Polylactic acid injections: usefullness for the treatment of facial lipoatrophy in HIV+ patients under tritherapy].
    Piquet M; Brignol L; Chatelain B; Rey D; Ricbourg B; Meyer C
    Rev Stomatol Chir Maxillofac; 2007 Dec; 108(6):496-504. PubMed ID: 17675198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of lipoatrophy and aging: volume deficits in the face.
    Coleman S; Saboeiro A; Sengelmann R
    Aesthetic Plast Surg; 2009 Jan; 33(1):14-21. PubMed ID: 18987910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison between lipofilling and a nonabsorbable filler for facial wasting rehabilitation in HIV-positive patients.
    Rauso R; Curinga G; Santillo V; Corvo G; Tartaro G
    J Craniofac Surg; 2011 Sep; 22(5):1684-8. PubMed ID: 21959413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Coleman lipostructure for treatment of facial lipoatrophy in patients with human immunodeficiency virus and parameters associated with the efficiency of this technique.
    Burnouf M; Buffet M; Schwarzinger M; Roman P; Bui P; Prévot M; Deleuze J; Morini JP; Franck N; Gorin I; Dupin N
    Arch Dermatol; 2005 Oct; 141(10):1220-4. PubMed ID: 16230558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Idiopathic hemi-facial lipoatrophy treated with autologous fat transfer.
    Liu SW; Cohen GF
    J Cosmet Dermatol; 2010 Sep; 9(3):226-9. PubMed ID: 20883296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effect of polyalkylimide gel injections on severity of facial lipoatrophy and quality of life of HIV-positive patients.
    Karim RB; de Lint CA; van Galen SR; van Rozelaar L; Nieuwkerk PT; Askarizadeh E; Hage JJ
    Aesthetic Plast Surg; 2008 Nov; 32(6):873-8. PubMed ID: 18551339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistence of lipoatrophy after a four-year long interruption of antiretroviral therapy for HIV1 infection: case report.
    Parruti G; Toro GM
    BMC Infect Dis; 2005 Oct; 5():80. PubMed ID: 16202141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polyacrylamide gel treatment of antiretroviral therapy-induced facial lipoatrophy in HIV patients.
    Mansor S; Breiting VB; Dahlstrøm K; Andersen AB; Andersen O; Christensen LH
    Aesthetic Plast Surg; 2011 Oct; 35(5):709-16. PubMed ID: 21359981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current treatment methods for combination antiretroviral therapy-induced lipoatrophy of the face.
    Kadouch JA; van Rozelaar L; Karim RB; Hoekzema R
    Int J STD AIDS; 2013 Sep; 24(9):685-94. PubMed ID: 23970569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous fat grafting and injectable dermal fillers for human immunodeficiency virus-associated facial lipodystrophy: a comparison of safety, efficacy, and long-term treatment outcomes.
    Shuck J; Iorio ML; Hung R; Davison SP
    Plast Reconstr Surg; 2013 Mar; 131(3):499-506. PubMed ID: 23142937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current perspectives on the management and prevention of antiretroviral-associated lipoatrophy.
    Phillips DR; Hay P
    J Antimicrob Chemother; 2008 Nov; 62(5):866-71. PubMed ID: 18703527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options.
    Mallewa JE; Wilkins E; Vilar J; Mallewa M; Doran D; Back D; Pirmohamed M
    J Antimicrob Chemother; 2008 Oct; 62(4):648-60. PubMed ID: 18565973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preliminary experiences with Bio-Alcamid in HIV facial lipoatrophy.
    Ramon Y; Fodor L; Ullmann Y
    Dermatology; 2007; 214(2):151-4. PubMed ID: 17341865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.